Alzheimer's Disease: A Pathogenetic Autoimmune Disorder Caused by Herpes Simplex in a Gene-Dependent Manner by Carter, C. J.
SAGE-HindawiAccess to Research
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 140539, 17 pages
doi:10.4061/2010/140539
Research Article
Alzheimer’s Disease: APathogeneticAutoimmuneDisorder
Caused byHerpes Simplex ina Gene-Dependent Manner
C.J.Carter
Polygenic Pathways, Flat 4, 20 Upper Maze Hill, Saint Leonard’s on Sea, East Sussex TN38 OLG, UK
Correspondence should be addressed to C. J. Carter, chris car@yahoo.com
Received 23 July 2010; Revised 27 September 2010; Accepted 22 October 2010
Academic Editor: Paula Moreira
Copyright © 2010 C. J. Carter. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Herpes simplex is implicated in Alzheimer’s disease and viral infection produces Alzheimer’s disease like pathology in mice.
The virus expresses proteins containing short contiguous amino acid stretches (5–9aa “vatches” = viralmatches) homologous
to APOE4, clusterin, PICALM, and complement receptor 1, and to over 100 other gene products relevant to Alzheimer’s disease,
which are alsohomologousto proteins expressed by other pathogens implicated in Alzheimer’s disease. Such homology, reiterated
attheDNAlevel,suggeststhatgeneassociationstudieshavebeen trackinginfection,aswellasidentifyingkeygenes,demonstrating
a role for pathogens as causative agents. Vatches may interfere with the function of their human counterparts, acting as dummy
ligands, decoy receptors, or via interactome interference. They are often immunogenic, and antibodies generated in response to
infection may target their human counterparts, producing protein knockdown, or generating autoimmune responses that may
kill the neurones in which the human homologue resides, a scenario supported by immune activation in Alzheimer’s disease.
These data may classify Alzheimer’s disease as an autoimmune disorder created by pathogen mimicry of key Alzheimer’s disease-
related proteins. It may well be prevented by vaccination and regular pathogen detection and elimination, and perhaps stemmed
by immunosuppressionor antibody adsorption-related therapies.
1.Introduction
Herpes simplex infection (HSV-1) has been shown to be
a risk factor in Alzheimer’s disease; acting in synergy with
possession of the APOE4 allele HSV-1 infection in mice
or neuroblastoma cells increases beta-amyloid deposition
and phosphorylation of the microtubule protein tau [1–
5]. Viral infection in mice also results in hippocampal and
entorhinal cortex neuronal degeneration, brain shrinkage,
and memory loss, all as found in Alzheimer’s disease [6]. A
recent study has also shown that anti-HSV-1 immunoglob-
ulin M seropositivity, a marker of primary viral infection or
reactivation, in a cohort of healthy patients, was signiﬁcantly
associated with the subsequent development of Alzheimer’s
disease. Anti-HSV-1 IgG, a marker of lifelong infection,
showed no association with subsequent Alzheimer’s disease
development[7].Allofthesefactorssupportaviralinﬂuence
on the development of Alzheimer’s disease. As shown below,
proteins expressed by HSV-1 are homologous to all of
the protein products of the major susceptibility gene in
Alzheimer’s disease (APOE, clusterin, complement receptor
1, and PICALM) as well as to APP and tau and over
100 others implicated in genetic association studies. This
suggests that Alzheimer’s disease is a “pathogenetic”disorder
caused by HSV-1 (and otherinfections) that mimic these key
susceptibility targets.
2.Methods
The Human herpesvirus 1 genome (NC 001798) was
screened against the human proteome using the NCBI
BLAST server with and without the Entrez Query ﬁlters
(“Alzheimer” or “cholesterol”) [8]. Each BLAST re-turns
a large list of human proteins, many of which display
homology to several diﬀerent HSV-1 proteins. A Tag
cloud generator was used to quantify these diﬀerent inter-
actions http://www.tagcloud-generator.com/index.php.T h i s
generates tags whose font size is proportional to the number
of viral protein hits per human protein. The tag size
scale was set from 1 to 20. Antigenicity (B cell epitope2 International Journal of Alzheimer’s Disease
Table 1: The antigenicity index (B cell epitope) for single amino
acids deﬁned by the BepiPred server. The top 6 scoring amino acids
are highlighted in grey in the various tables.
Symbol Amino acid B-epitope
antigenicity
P Proline
G Glycine
D Aspartate
E Glutamate
S Serine −0.008
T Threonine −0.011
Q Glutamine −0.012
N Asparagine −0.013
A Alanine −0.024
W Tryptophan −0.025
K Lysine −0.031
R Arginine −0.062
H Histidine −0.071
V Valine −0.112
F Phenylalanine −0.138
I Isoleucine −0.138
M Methionine −0.138
C Cysteine −0.175
0.003
0.035
0.145
0.018
prediction) was predicted using the BepiPred server [9]a t
http://www.cbs.dtu.dk/services/BepiPred/andTcellepitopes
predicted using the Immune epitope database resource at
http://tools.immuneepitope.org/main/html/tcell tools.html
[10]. The immunogenicity index for individual amino
acids is shown in Table 1. References for genetic association
studies can be foundat http://www.polygenicpathways.co.
uk/alzpolys.htm. References for herpes simplex host viral
interactions can be found in a database at http://www.poly-
genicpathways.co.uk/herpeshost.html. Protein kinases phos-
phorylatingthemicrotubuleproteintauwere identiﬁed from
the Kinasource database at http://www.kinasource.co.uk/
Database/welcomePage.php and from the material available
at the ENTREZ gene interaction section for tau (MAPT).
Because of the large volume of data generated by the
BLASTs, raw BLAST data have been made available at http://
www.polygenicpathways.co.uk/Alzheimer.htm.T h i ss u r v e y
is restricted to the herpes simplex virus, HSV-1, but similar
data were obtained for other viral or pathogen species
implicated in Alzheimer’s disease, where similar conclusions
apply. These BLAST ﬁles and a summary of the results are
available on the PolygenicPathways website at http://www
.polygenicpathways.co.uk/BLASTS.htm.
3.Results
The results of the HSV-1 BLASTS, sized according to the
number of viral hits per protein, using the ﬁlter “Alzheimer,”
are shown in Table 2. Over a hundred human gene products,
including all of the major Alzheimer’s disease susceptibility
gene products (APOE4, clusterin, complement receptor 1,
and PICALM) and most of many other diverse genes that
have been implicated in Alzheimer’s disease in genetic as-
sociation studies contain intraprotein sequences that are
identical to those within herpes simplex viral proteins. The
alignment with complementreceptor 1 (CR1)has functional
consequences, as glycoprotein C of the virus acts as a
CR1 mimic, binding to other complement components (C3
and its derivatives) blocking the complement cascades and
preventing formation of the membrane attack complex [12,
13].Thisnicelyillustratesoneofthefunctionalconsequences
of this type of mimicry.
The type of viral homology for various diﬀerent protein
classes is shown in Table 3. These classes include products
involved in APP signalling and processing (BACE1and 2and
gamma-secretase components), cholesterol and lipoprotein
function, tau function, inﬂammation, and oxidative stress,
all of which are key processes disrupted in the Alzheimer’s
disease brain.
Using the ﬁlter “cholesterol,” a number of cholesterol
and lipoprotein-related proteins again contain numerous
sequences corresponding to those found in herpes viral
proteins. This group of proteins play an important role in
Alzheimer’s disease pathophysiology [14–17].
The unﬁltered BLAST returns the human proteins with
the greatest homology to viral proteins and showed that
herpes simplex viral proteins are highly homologous to
a series of family members of diverse protein kinases.
Severalof these are known to phosphorylate the microtubule
protein tau,a ne ﬀect that is observed following HSV-1
infection [5]. The homology is such as to suggest that such
phosphorylation may be accomplished by the viral proteins
themselves, as well as by human protein kinases (Table 4).
This type of mimicry is by no means restricted to
the herpes simplex virus as APOE4, clusterin, complement
receptor 1, and PICALM are homologous to proteins from
a diverse array of phages and viruses including phages that
aﬀectcommensalbacteria,theinﬂuenzavirus,andtheHHV-
6 virus which has a seroprevalence approaching 100% [18]
(Table 5). Because of the universality of the phenomenon of
viral matches within the human proteome, most proteins
will be homologous to proteins from speciﬁc subsets of
viruses. Viruses and other pathogens expressing proteins
with homology to key susceptibility gene products might
howeverbeconsideredasimportant potentialenvironmental
risk factors. For the major Alzheimer’s disease gene candi-
dates, several herpes species other than HSV-1 (HSV-2, 3, 6,
6B, and 8) fall into this category (Table 5).
The tables in supplementary data on the website http://
www.polygenicpathways.co.uk/alzheimer.htm show that nu-
merous Alzheimer’s disease susceptibility gene products are
also homologous to proteins expressed by other pathogen
risk factors in Alzheimer’s disease, including Chlamydia
pneumonia, which has recently been detected in the Alz-
heimer’s disease brain [19].
Cryptococcus neoformans, Helicobacter pylori, Porphy-
romonas gingivalis (one cause of the gum disease that is a
risk factor in Alzheimer’s disease [20]), Borrelia Burgdorferi,International Journal of Alzheimer’s Disease 3
Table 2: Human proteins with homology to HSV-1 proteins: The size of symbol (HUGO Nomenclature approved gene symbols) is
proportional to the number of viral proteins displaying homology to the gene product. Filter “Alzheimer”: all of the genes encoding for
these proteins with the exception of those with the strikethrough have been implicated in Alzheimer’s disease in genetic association studies.
Filter “cholesterol”: genes encoding for proteins products in dashed boxes have been implicated in Alzheimer’s disease in genetic association
studies. No Filter: HSV-1 proteins are most homologous to diverse families of kinases: Those boxed have been shown to phosphorylate the
microtubule protein tau (Data from Kinasource and from NCBI Interactions section for the MAPT gene (tau)).
BLAST ﬁlter Gene products with homology to HSV-1 proteins
HSV-1 Filter
“Alzheimer”
Hsv-1 Query
Cholesterol4 International Journal of Alzheimer’s Disease
Table 2: Continued.
BLAST ﬁlter Gene products with homology to HSV-1 proteins
HSV-1 No Filter
[21], Human herpesvirus 6, and Human herpesvirus 5
(Cytomegalovirus) [22].
Cryptococcus neoformans infection has been shown to
beassociated with arare butcurableformofdementiaintwo
separate studies, where both patients had been consigned to
healthcare for 3 years, with a diagnosis of Alzheimer’s dis-
ease. Both recovered normal function following antifungal
treatment [23, 24]. Heliocobacter pylori eradication has also
been reported to improve cognitive function in Alzheimer’s
disease [25].
The protein sequences highlighted in grey in Table 3
contain strings of herpes simplex proteins that have been
showntobindtoseveralinteractomepartners oftau[11](see
http://www.polygenicpathways.co.uk/herpeshost.htm)a n d
are those most likely to form epitopes that cross-react with
their human counterparts (Table 1). These include APOE4,
complementreceptor1, clusterin,insulin degrading enzyme,
the APP homologue, APLP2, the APP binding protein
APBBI1P, the collagen amyloid plaque component CLAC,
synuclein, and the foetal Alzheimer antigen, ALZ50. Tau
appears to be highly antigenic (Table 2).
This antigenicity was further studied for the two key
proteins in Alzheimer’s disease, beta-amyloid and tau,a n d
the predicted immune epitopes compared with the HSV-1
viralproteinsaligningwithin thesevariousregions(Figures2
and 3).
4.Vatches withinBeta-Amyloidand the
MicrotubuleProteintau
Vatches (= viralmatches) are short contiguous amino acid
stretches that are identical in viral and human proteins
[26, 27]. There are several million within the human
proteome, derived from evolutionary descent and from
the insertion of multiple viruses into the human genome
over millions of years. This type of insertion is not
restricted to retroviruses, as herpes viruses, hepatitis viruses,
inﬂuenza and the common cold virus, the coronavirus, and
the papillomavirus, among others, have all been inserted
into diﬀerent genomic regions or are homologous to the
encoded protein products. This has occurred on several
occasions during evolutionary time, and these reinsertions
appear to be responsible for the creation of gene families
(seehttp://www.polygenicpathways.co.uk/blasts.htm),where
over2million suchalignmentsareavailableformultipleviral
species. In eﬀect, the entire human genome appears to be
composedofviralDNA.Forexample,thecoverageofhuman
chromosome 10iscomplete,with 119,867human/viral DNA
matches.
A single HSV-1 vatch, translated back to DNA, is
i d e n t i c a lt oD N Ai n1 0 3d i ﬀerent genomic regions covering
several human chromosomes. This phenomenon is likely
responsible for the creation of gene families, and the HSV-1International Journal of Alzheimer’s Disease 5
Table 3: Major susceptibility gene products and members of other key signalling networks in Alzheimer’s disease (Sbjct) aligning with the
translated HSV-1 genome (Query). The 6 amino acids with the highest B cell antigenicity index are highlighted in grey (see Table 1). Spaces
denote a nonidentical amino acid; dashes represent gaps and + = conserved amino acid (similarphysicochemical properties).
Human protein Alignment with the HSV-1 translated genome
APOE4
1B68A GI:15826311
Query 139585 V L R G R V
VRG RLV
V L R G R V
139568
Sbjct 111 116
PICALM NP 009097.2
phosphatidylinositol binding clathrin
assembly protein
Query 35856 T P T T A P
PA TTPT
T P T T A P
35873
Sbjct 601 606
Complement receptor 1 complement
receptor type 1 isoform S precursor
NP 000642.3
Query 39696 R P P P S S
SSPPPR
R P P P S S
39679
Sbjct 2029 2034
Clusterin isoform1 NP 001822
Query 48155 R A G G P S
SPGGAR
R A G G P S
48138
Sbjct 30 35
APP processing and related
3DXCA chain A, crystal structure of the
intracellular domain of human APP in
complex with Fe65
Query 78347 G L V A E T
TEAVLG
G L V A E T
78364
Sbjct 64 69
EAX09965.1 amyloid beta (A4)
precursor protein (peptidase nexin-II,
Alzheimer)
Query 102020 RD P S E LRNTAAS G PD
RDP
RDP VKLP TTAAS TP D
L TAAS PD
102064
Sbjct 359 373
NP 958816.1 amyloid beta A4 protein
isoform b precursor
Query 75494 AEEIAD QV-E ILVD QTE
AEEI
AEEIQD E VD E LL--QKE
D+ VE L QE
75447
Sbjct 536 550
NP 620428.1 beta-secretase 1 isoform B
preproprotein
Query 96347 V G A G L W L L S W
W
V G A G M W L L L W
LLW+GAGV
96376
Sbjct 7 16
NP 620477.1 beta-secretase 2 isoform B
preproprotein BACE2
Query 148387 ARATL-P VMKE LLLRAAP E
ARA
ARALLLP LLAQWLLRAAP E
L P LLRAAPE
148334
Sbjct 5 23
AAM92013.1beta-site APP-cleaving
enzyme BACE1
Query 59005 IFD RTRKFVLACP RAG F
+FDR
V F DR A R K ------R I GF
V Q C A S V A
AVSAC+V
V H C A S V A
RK R GF
58955
Sbjct 59 69
Query 115596 115576
Sbjct 70 76
EAW81096.1 presenilin 1 (Alzheimer
disease 3), isoform CRA f
Query 134424 W A V T W E P L F
+LPEWT AW
W A - T W E P L Y
134398
Sbjct 240 247
EAW69799.1 presenilin 2 (Alzheimer
disease 4), isoform CRA d
Query 40896 S I P L P P L A
ALP
S I P L A P L A
LPIS
40873
Sbjct 152 1596 International Journal of Alzheimer’s Disease
Table 3: Continued.
Human protein Alignment with the HSV-1 translated genome
NP 758844.1 gamma-secretase subunit
PEN-2
Query 151699 S R W V Y G
G YVWRS
S R W V Y G
W F L G G V A S
S AVG LFW
W F L F G V A S
151716
Sbjct 55 60
Query 142209 142186
Sbjct 60 67
NP 004960.2 insulin-degrading enzyme
isoform 1 precursor
Query 25849 G P Y E R R D E P
PED EY 
G R Y E R K D E P
G R
25875
Sbjct 58 66
NP 061916.3 amyloid beta A4 precursor
protein-binding family B member
interacting protein APBB1IP
Query 26756 DN H L PSPA PPT P- DDI SC GPEL PF A RP P
D+
D D FLPPPPPPPPL DD----
LPP PPP DD PELP PP
PEL P- - - -PP
26673
Sbjct 551 571
NP 004877.1 amyloid beta A4 precursor
protein-binding family A member 3
[Homo]
Query 148163 E P P R G L R L L R S A P E L
LEP
E P P Q - - - L L R P A P E L
A RLL PPE
148119
Sbjct 132 143
NP 001633.1 amyloid-like protein 2
isoform 1 APLP2
Query 73214 I SM T PV A V L W EN PDPPGPPDV R F V GS EA T EEL P
IS
IS E
T E Y Y Y V D T R - E V V E
EVVE
T D Y Y Y - D - R D E V V E
TPV DVR V SE EE
T PV ------------ - DV R V SS EESEEI P
P
R - D YYY+T
73116
Sbjct 579 597
Query 63557 63595
Sbjct 266 277
NP 001123886.1 amyloid beta A4
precursor protein-binding family A
member 2 isoform
Query 20300 L D G D G R R L
LRRGDGDL
L D G D G R R L
20323
Sbjct 212 219
AAL79526.1AF394214 1 adaptor
protein FE65a2
Query 63303 H S P T W L G R T S S
SS
H S P T W Q E R S S S
R WTPSH
63335
Sbjct 572 582
NP 663722.1 amyloid beta A4 precursor
protein-binding family B member 1
isoform
Query 51630 I L V P G R L G R
RGLRGP
I L G P G R L G R
LI
51604
Sbjct 130 138
Query Q12830.3BPTF Fetal Alzheimer
antigen
Alz-50 clon
Query 41203 PA PPPF R SA R N T C PL PPSPT A SGP
PAPPP
PA PPP
PP P SGP
PPPPPT SGP --------- Sbjct 22
Query O94985.1 CSTN1
Calsyntenin-1 = Alcadein
Query 43114 L L L R S A
A
L L L R A A
RLLL
43131
Sbjct 12 17
NP 009292.1 alpha-synuclein isoform
NACP112
Query 54520 V G A V G H V A D E
E
V T A V G H V V G E
VHGVA V
54549
Sbjct 46 55
Others
Query
Q07954.1LRP1 HUMAN RecName:
Full=Prolow-density lipoprotein
receptor-related protein
Query 92727 G S G T E R H I T
T+HRETGSG
G S G T E R H V T
92701
Sbjct 1425 1433International Journal of Alzheimer’s Disease 7
Table 3: Continued.
Human protein Alignment with the HSV-1 translated genome
NP 000577.2 interleukin-2 precursor
Query 27667 S S S T P A S
SAPTSSS
S S S T P A S
27647
Sbjct 20 26
NP 002084.2 glycogen synthase
kinase-3 beta isoform1
Query 86718 S T T R P R G
GRPRTTS
S T T R P R G
86698
Sbjct 3 9
NP 065574.3 choline
O-acetyltransferase isoform2 [Homo
sap]
Query 67995 AQS AE PRRA----CVP
A+
AE AAE PRRAG P HLCIP
AEPRRA C+P
68030
Sbjct 87 102
NP 003947.1 cholesterol 25-hydroxylase
Query 66447 R R L A P V W
WVPALRR
R R L A P V W
66467
Sbjct 64 70
Table 4:Alignmentof the HSV-1translated genome(Query) with 3protein kinasesknownto phosphorylate tau (Sbjct). Glycogen synthase
kinase GSK3A aligns with the same amino acids as GSK3B. CAMK2B: calcium/calmodulin-dependent protein kinase II beta. MAPK1:
mitogen-activated protein kinase 1 (erk2).
Kinase Alignment with HSV-1 proteins
GSK3B and GSK3A
Query 136083 QLLSAVDYIHRQGIIHRDIKTENIFINTPE----DICLGDFGAA-------------CFV
QL C
QLFRSLAYIHSFGICHRDIKPQNLLLD-PDTAVLKLC—DFGSAKQ LVRG EPNVSYIC--
G A S W I D V T T T Y P D G A - - L V E P A N T D I T G A I G Y P F P S S R S G Q
SR
G A S W V D I S S T Y - D T A G F I L E P A R Y - - - - - - - Y - - - - - R S - -
C L A A A G P A T R S R - - - - W P H
HPW
C L A I A E P P T R P R F V K T W P H
YIH GI HRDIK +N + P+ C DFG A
Y APE A DYT +D+WSAG
RR TPAAL C
Sbjct 143
Query 136212 136328
Sbjct 198 223
Query 81948 81992
Sbjct 278 296
CAMK2B
Query 136083 QLLSAVDYIH-RQ-GIIHRDIKTENIFINTPEDI-----C------LGDFGAACFVQG VQG --
QL
QILXAV--LHCHQMGVVHRDLK--------
I V L G A S W I D V T T T Y P D G A L V E P A N T D I T G A I G Y P F P S S R S -
+GA G T
I V - G C A W I D V P K G Y A E K R L V E P S L Y G P T G A F G F - - - - - W A Q
PEVL + Y VDIW G VI
AV VQG DFG A L C PE+ K G++HRD H  Q
136217
Sbjct 119
Query 136218 136337
Sbjct 169 203
MAPK1
Query 136083 QLLSAVDYIHRQGIIHRDIKTENIFINTPEDIC----LGDFGAACFVQGSRSSPFPYGI
QLL
QLLRGLKYIHSAGIIHRDLKPSNVAVN--ED-CELRIL-DFGLA------RQ-------A
G A S W I D V T T T Y P D G A - - - - - L V E P A N - - - T D I T G - - - - -
G+
G V S W I D V T Q N Y - - - - H M W N L M I E P A R Y W R T A V Y G T M E E D
YIH GIIHRDK N+ +N EDC L DFG A R
T APE++ Y TVDIWS G
Sbjct 133 175
Query 136251 136328
Sbjct 176 210
virus appears to have been partly responsible for the creation
of lipoprotein receptor families (Figure 1), and of numerous
kinases within a number of diﬀerent families (see above
and Table 2). Over millions of years, these DNA inserts have
been extensively shuﬄed by recombination, but millions of
consecutive sequences are retained that encode for the viral
matching protein components.
Some of the vatches within beta-amyloid and tau are
illustrated in Figures 2 and 3 which also demonstrates the
B cell and T cell antigenicity of these proteins. As can
be seen, there are numerous HSV-1 vatches within both
proteins, many of which correspond to highly antigenic
regions of APP or tau, and therefore also of the HSV-1
proteins.
In addition to the herpes simplex virus, a large number
of other viruses express proteins containing a VGGVV
sequence that is identical to that of a C-terminus peptide
within beta-amyloid. Although not the most immunogenic8 International Journal of Alzheimer’s Disease
Table 5: Other viruses expressing homologousproteins for the four major Alzheimer’s disease susceptibility gene products.
Alzheimer’s gene Viral protein Identical amino acid sequences (vatches)
APOE4
Chain A,
Apolipoprotein E4
(Apoe4), 22k
Fragment.
ACCESSION
1B68 A
ACE82482 polyprotein Hepatitis C virus subtype 1a GADMEDV
MKELKA
RKRLLR+++LK L
RKR---- D+LQ-RL--- A-G-REGAE-GLS
EEPPQ WQSGQ
EEP -P--- Q--WQSGQ
LEEQLT--
--
A
DDL--
-
R-LAVYQA
MTR-- EFLKVA-Q
-
YP 002455799 tape measure protein Lactobacillus phage Lv-1
ADD95207 hypothetical protein uncultured phage
MedDCM-OCT-S04-C650
YP 002242088 gp31 Mycobacterium phage Konstantine
YP 002922735 gp63 Burkholderia phage BcepIL02
NP 612835 major capsid protein Clostridium phage phi3626
AAT07716 virion protein human herpesvirus 3
DAA06495 envelope glycoprotein 24 human herpesvirus 5
YP 001293401 hypothetical protein PPF10 gp057 Pseudomonasphage
F10
Clusterin isoform1
NP 001822.2
ACS93434 capsid portal protein human herpesvirus 5 QVAERL
SAINT
L+Q TV SD+
and
LLEEK D
A LRRELD
ESGQ LG
GSGLV R+L+F
+SGQVLG--T
LIEKTN++
CAA35329 HCMVUL127 human herpesvirus 5
T44166 hypothetical protein U20 imported—human herpesvirus 6
(strain Z29)
AF157706 21 U20 human herpesvirus 6B
P60504ICP47 HSV2S ICP47 protein;
NP 044506 large tegument protein human herpesvirus 2
AAR12147 US34 human herpesvirus 5
AAA66443 unknown protein human herpesvirus 2
D1LR45 9INFA D1LR45 Hemagglutinin Inﬂuenza A virus
Clusterin isoform2
NP 976084.1
ACS93434 capsid portal protein human herpesvirus 5 QVAERL
KYVNKEand LIEKTNE
KKKKEDAL
EECKPCK
DDDRTVC
NETRE
EKALQEYL
RKYELLK
LLEQLNE+
TEFIREG
C3U7E2Inﬂuenza A virus
C3VE93 Envelope glycoprotein (Fragment) human immunodeﬁciency
virus
D2XAW9 Restriction endonuclease Marseillevirus
Q5J5Q8 Gp46 Mycobacterium phage
Q9DVL9 9HIV1 Q9DVL9 Envelope glycoprotein gp160 human
immunodeﬁciency virus
ORF10 Vibrio phage
Q2PZB7 RstR-like protein Vibrio phage CTX
P36272 Portal protein Enterobacteria phage P21
Clusterin isoform3
NP 001164609.1
ACS93434 capsid portal protein human herpesvirus 5 QVAERL and
RVGSGLV R+L+F
L+Q TV SD+
DESLQ A
SGVTEV
ESGQ LG
+SGQVLG T
LIEKTN++
NP 050200 glycoprotein human herpesvirus 6
NP 050228 glycoprotein O human herpesvirus 6
YP 001129444 BFLF1 human herpesvirus 4 type 2
NP 044506 large tegument protein human herpesvirus 2
AAA66443 unknown protein human herpesvirus 2
D1LR45 Hemagglutinin Inﬂuenza A virus
CR1 isoform f
NP 000564.2
ACL67924 single-stranded DNA-binding protein human herpesvirus 3 FSCEPSD
WDPPLKC
SVPVCE
Y+LRGAA
VRAGC TPE
+RCRRK
L+GSSATC
HCVL-GMK
Y+LRGAA
P88903 HHV8 P88903ORF 4 human herpesvirus 8 type M PE = 4S V= 1
AAD49671AF157706 89 U79 human herpesvirus 6B
ABI63477 UL15 human herpesvirus 1
CAB06775 UL15 human herpesvirus 2
ACN63150 pUL27 human herpesvirus 5
ACS92020 tegument protein UL14 human herpesvirus 5
NP 042926 protein UL49 human herpesvirus 6
BAA78254 capsid protein human herpesvirus 6B
ABI63477 UL15 human herpesvirus 1
NP 044484 DNA packaging terminase subunit 1 human herpesvirus 2International Journal of Alzheimer’s Disease 9
Table 5: Continued.
Alzheimer’s gene Viral protein Identical amino acid sequences (vatches)
CAA35376 HCMVUL61 human herpesvirus 5 GPPAPLP
WDPPL-KC
GSVVTYCNG
:Q01016-2 Q01016 Isoform 2 of Complement control protein homolog
Saimiriine herpesvirus 2
:Q01016-2 Q01016 Isoform 2 of Complement control protein homolog
Saimiriine herpesvirus 2 (strain 11)
CR1 isoform S
NP 000642.3
Q2HRD4 ORF4 human herpesvirus 8 type P (isolate GK18) WDPPLKC
SVPVCE
SSPPPR
HCVLGMK
GPPAPLP
Y+LRGAA
TI NGDF
WDPPLKC
ACL51139 helicase-primase primase subunit human herpesvirus 5
NP 050259 DNA replication human herpesvirus 6
AAD49671AF157706 89 U79 human herpesvirus 6B
AAR84398 ORF 03L Herpes simplex virus 1 strain R-15
CAA58413 U33 human herpesvirus 6
BAA78254 capsid protein human herpesvirus 6B
CAA35376 HCMVUL61 human herpesvirus 5
NP 044484 DNA packaging terminase subunit 1 human herpesvirus 2
NP 042966DNA replication origin-binding helicasehuman herpesvirus 6
Q2HRD4 ORF4 human herpesvirus 8 type P (isolate GK18)
PICALM
NP 001008660.1
AAR84403 ORF 08L Herpes simplex virus 1 strain R-15 TGSAVS
SLTTAA-P
FD-LGGLL
LKEQ-LK
NPFLT- SG
FTPSPV
IRLFAA-YN+
LKALKEQ-L
SKTVCK T
MVY-NERF
QYLA-RNT
STWGD FS
TEKLLKT + II
ATVDA DDAI
IRLFAAYN+
ITTHHL--MV
TEKLLKT II
ALEQLK ALKE+
- -- +
-
ABX74960 dihydrofolate reductase-like protein Retroperitoneal
ﬁbromatosis-associatedherpesvirus
CAA32311 very large tegument protein human herpesvirus 1
AAP88252 UL74 protein human herpesvirus 5
ABF22039 DNA polymerase catalytic subunit human herpesvirus 3
BAA86355 polyprotein Hepatitis C virus
NP 899479 hypothetical protein KVP40.0233 Vibrio phage KVP40
ADD94131 hypothetical protein uncultured phage
MedDCM-OCT-S04-C1161
NP 671655 EVM136 Ectromelia virus
AAM92151AF436128 1 putative transformingprotein E6 human
papillomavirus—cand89
YP 002727871 putative structural protein Pseudomonasphage phikF77
AAT73600 minor tail protein Lactococcus phage 943
BAE44071 polyprotein human coxsackievirus A24
ADD25709 putative phage structural protein Lactococcus phage 1358
NP 899479 hypothetical protein KVP40.0233 Vibrio phage KVP40
YP 238567 ORF319 Staphylococcus phage Twort
BAE44071 polyprotein human coxsackievirus A24
YP 002332459 hypothetical protein PPMP29 gp34 Pseudomonasphage
MP29
ofsequences,thisepitopehasbeenusedtolabelbeta-amyloid
in Alzheimer’s disease brain [28]( Figure 2).
5.HSV-1ProteinsBind to the
Interaction Partners of tau
Because HSV-1 proteins are homologous to portions of the
tau protein, one might expect the viral proteins to interfere
with tau binding partners. This is indeed the case, as diverse
herpes simplex viral proteins have been shown to bind to
several of the interactome partners of tau (Table 6).
6.Discussion
Almost without exception, the genes encoding the
proteins that match HSV-1 sequences (using the ﬁlter
“Alzheimer”) have been reported as genetic risk fac-tors
in Alzheimer’s disease (see http://www.polygenicpathways.
co.uk/alzpolys.html) suggesting that such studies have been
tracking HSV-1 (and other) infections over the years and
inadvertently demonstrating that HSV-1 causes Alz-heimer’s
disease. This in no way detracts from the importance of
these studies, but reﬂects a phenomenon that is probably
common to most diseases. Because of ourlikely evolutionary10 International Journal of Alzheimer’s Disease
Table 6: The binding partners of tau (from the interaction section of NCBI gene) and their interaction with herpes simplex proteins (from
the Wikigenes database) [11]; https://www.wikigenes.org/e/art/e/61.html.
Gene symbol Name Interaction with HSV-1 proteins
AATF Apoptosis antagonizingtranscription factor —
ABL1 V-abl Abelson murine leukemia viral oncogene homolog1 —
ACTB Actin, beta Virion component
APOE Apolipoprotein E Binds to glycoprotein B
BAG1 BCL2-associated athanogene —
CALM1 Calmodulin 1 (phosphorylase kinase, delta) Phosphorylated by ICP10
CAMK2A Calcium/calmodulin-dependent protein kinase(CaM kinase)
II alpha —
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin
1, beta, convertase) —
CASP3 Caspase 3, apoptosis-related cysteine peptidase US3 phosphorylates procaspase 3
CASP6 Caspase 6, apoptosis-related cysteine peptidase —
CASP7 Caspase 7, apoptosis-related cysteine peptidase Activated during HSV-1 mediated apoptosis
CASP8 Caspase 8, apoptosis-related cysteine peptidase Activity inhibited by LAT latency transcript
CDK1 Cyclin-dependent kinase 1 —
CDK5 Cyclin-dependent kinase 5 —
FLJ10357 Hypothetical protein FLJ10357 —
FYN FYN oncogene related to SRC, FGR, YES —
GSK3A Glycogen synthase kinase 3 alpha —
GSK3B Glycogen synthase kinase 3 beta Activated by HSV-1 infection
HSPA8 Heat shock 70kDa protein 8 Recruited to nuclear domains following infection:
ICP0 dependent
MAPK12 Mitogen-activated protein kinase 12 —
MAPT Microtubule-associated protein tau Phosphorylated by viral infection via GSK3B and
PRKACA
MARK1 MAP/microtubule aﬃnity-regulating kinase 1 —
MARK4 MAP/microtubule aﬃnity-regulating kinase 4 —
OGT
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-
N-acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase)
—
PARK2 Parkinson disease (autosomalrecessive, juvenile) 2, parkin —
PHKG1 Phosphorylase kinase, gamma 1 (muscle) —
PIN1 Protein (peptidylprolyl cis/trans isomerase)
NIMA-interacting 1 —
PKN1 Protein kinase N1 —
PPP2CA Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha
isoform —
PPP2CB Protein phosphatase 2 (formerly 2A), catalytic subunit, beta
isoform —
PPP2R5A Protein phosphatase 2, regulatory subunit B , alpha isoform —
PPP5C Protein phosphatase 5, catalytic subunit —
PRKCD Protein kinase C, delta —
PSEN1 Presenilin 1 (Alzheimer disease 3) —
RPS6KA3 Ribosomal protein S6 kinase, 90kDa, polypeptide 3 —
RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 —
S100B S100 calcium binding protein B —International Journal of Alzheimer’s Disease 11
Table 6: Continued.
Gene symbol Name Interaction with HSV-1 proteins
SNCA Synuclein, alpha (non-A4 component of amyloid precursor) —
SPTB Spectrin, beta, erythrocytic (includes spherocytosis, clinical
type I) —
STAU1 Staufen, RNA binding protein, homolog1 (Drosophila) —
STUB1 STIP1 homology and U-box containing protein 1 —
STXBP1 Syntaxin binding protein 1 —
TUBA4A Tubulin, alpha 4a —
TUBB Tubulin, beta —
UBC Ubiquitin C Virion component
YWHAB Tyrosine 3-monooxygenase/tryptophan5-monooxygenase
activation protein, beta polypeptide —
YWHAZ Tyrosine 3-monooxygenase/tryptophan5-monooxygenase
activation protein, zeta polypeptide Virion component
Proteins  Chromosome
LRP1 12q13-q14
LRP1B 2q21.2
LRP2 2q24-q31
LRP3 19q13.11
LRP4 11p11.2
LRP5 11q13.4
LRP6 12p13.2
LRP8 1p34
LRP11 6q25.1
SORL 11q23.2-q24.2
SORL1 11q23.2-q24.2
LDLR 19p13.3
VLDLR 9p24
HSV-1 protein BLAST versus  human proteins:  filter = lipoprotein
Distribution of 171264 BLAST hits on the query sequence 
Mouse-over to show defline and scores, click to show alignments
Color key for alignment scores
0 30000 60000 90000 120000 150000
Query
<40 40–50 50–80 80–200 200
Figure 1:The BLASTresultforHSV-1proteins (translatedviralgenomeversushumanproteins) usingtheﬁlter“lipoprotein.”The repetitive
patterns in the pictogram reﬂect homologywith a number of diﬀerent lipoprotein receptors located on diﬀerent chromosomes,as shownin
the table.
descent from viruses, ﬁrst opined by J.B.S. Haldane and
Francois D’Herelle almost a century ago [29, 30], our
genomes contain traces of this descent which are transcribed
into these short contiguous amino acid stretches (vatches)
that exactly match many of the proteins in the current
virome. Repeated viral insertions also add several genes to
the human genome at once, a phenomenon that is likely
responsible for evolutionary jumps, as suggested by others
[31]. The idea that higher forms of life originated from
viruses, although contentious, is supported by the fact that
the entire human genome appears to be comprised of viral
DNA. For example a BLAST of human chromosome 10
against all viral genomes (DNA versus DNA) returned
119,867 hits, covering the entire chromosome, with no
gaps, in both inter- and intragenic regions (see http://
www.polygenicpathways.co.uk/viralimages.htm). Similar re-
sults were obtained for other chromosomes. Our genomes
and polymorphisms thus determine which vatches we
possess, which viruses pose the threat, and which viral-
related disease we are likely to develop. Whether we develop12 International Journal of Alzheimer’s Disease
the disease in question will depend on our encounters
with the virus, whether we are vaccinated, and no doubt
on our HLA-antigens and immune background related to
the elimination of self-antibodies soon after birth.
This phenomenon appears tob eu n i v e r s a l ,a sv a t c h e s
have been found in the XMRV virus, relating to human
proteins involved in mitochondrial respiration and prostate
cancer, in the Epstein-Barr virus, which matches multiple
sclerosis autoantigens [27], in the AIDS virus which targets
vatches in over 50 components of the human immune
network, in the papillomavirus which targets cervical can-
cer oncogenes, and in the HSV-2 virus which targets
schizophrenia susceptibility gene products (see http://www.
polygenicpathways.co.uk/BLASTS.htm). It is even relevant
to human genetic diseases as the polyglutamine repeats
observed in Huntington’s disease and spinocerebellar ataxias
align with very common viruses (the ubiquitous HHV-6)
while the cystic ﬁbrosis mutant aligns with pseudomonas
and staphylococcal phages, whose bacterial hosts have been
found to shorten the lifespan of these patients. The London
mutation in Alzheimer’s disease converts the surrounding
peptide to a vatch that is homologous to proteins from the
rhinoviruses that cause the common cold [26, 27, 32, 33].
Everyhumanprotein sofar screenedby theauthor,withouta
single exception, displays this type of homology to particular
butspeciﬁc sets ofvirus for each protein. Similarly all viruses
so far screened (∼30) express proteins with homology to a
large but speciﬁc subset of human proteins.
These viral homologues may interfere with Alzheimer’s
disease pathological pathways in a number of ways. Firstly,
as demonstrated by the complement receptor 1 HSV-1 viral
mimic, the viral protein can substitute for its human coun-
terpart, presumably diverting its function towards diﬀerent
compartments. Secondly,as theyare clearly abletosubstitute
for their human counterparts, they are likely to interfere
with their protein/protein networks (interactome). This was
clearly demonstrated for tau, where herpes simplex virus
proteins do indeed bind to tau binding partners.
As many of these matching sequences are highly
immunogenic, antibodies to the virus may also target the
humanhomologue,ineﬀectproducingaproteinknockdown
and reproducing the eﬀects, but on a massive scale, seen
in various Alzheimer’s disease-related knockout mice [34–
39]. Such immunogenic viral proteins may also generate
antibodies capable of mounting an immune attack against
their human counterparts, killing the cells in which they
reside by immune and inﬂammatory mechanisms, and by
complement-related lysis (see below).
7.The DangersofAutoimmunity
The immunogenic proﬁle of some of these homologues may
also be responsible for the neurodegeneration and patholog-
ical features observed in Alzheimer’s disease. Antibodies to
the human proteins may result in immune, inﬂammation,
and complement pathway activation, killing the cells in
which the human homologue resides. There is a great deal of
evidence supporting autoimmune attack in the Alzheimer’s
disease brain.
A number of immune-system-related proteins are found
in amyloid plaques or neuroﬁbrillary tangles. Interleukin 1
alpha, interleukin 6, and tumour necrosis factor are all been
localisedwithinplaques,andacutephaseproteinsinvolvedin
inﬂammation, such as amyloid P, alpha-1 antichymotrypsin,
and C-reactive protein are also plaque components while
immunoglobulin G is located in the plaque corona [14, 40–
42]. Large increases in IgG levels have been recorded in
the brain parenchyma, in apoptotic dying neurones, and
in cerebral blood vessels in the Alzheimer’s disease brain
[43]. Complement component C3 is found in Alzheimer’s
disease amyloid plaques along with complement C4 [44].
Complement components Clq, C3d, and C4d are present in
plaques,dystrophicneuritis, andneuroﬁbrillary tangles[45].
T h em e m b r a n ea t t a c kc o m p l e x( M A C ) ,c o m p o s e do f
complement proteins C5 to C9, forms a channel that is
inserted into the membranes of pathogens, destroying them
by lysis. These components cannot be detected in temporal
cortex amyloid plaques in Alzheimer’s disease [41, 44, 46].
However the MAC complex is present in dystrophic neurites
and neuroﬁbrillary tangles [45], and others have detected
this complex in neuritic plaques and tangles, along with
deposition of C1q, C3, and clusterin [47]. The membrane
attack complex has also been detected in the neuronal
cytoplasm in AD brains and associated with neuroﬁbrillary
tangles and lysosomes [46].The presence of the MAC
complex in neurones might suggest thatneuronal lysis by the
MAC complex could contribute to neuronal cell death [45].
The microtubule protein tau was one of the more
a n t i g e n i cp r o t e i n sr e v e a l e di nt h i ss u r v e ya n do n ew i t h
numerous matches to herpes viral proteins that would
be equally immunogenic. Immunisation with tau in mice
produces tauopathy, neuroﬁbrillary tangles, axonal damage,
and gliosis [48] demonstrating the dangers of autoimmunity
in a manner directly relevant to Alzheimer’s disease.
Beta-amyloid autoantibodies are common in the ageing
population and in Alzheimer’s disease and may be related
to herpes simplex and numerous other viruses or phage
proteins that exactly vatch a VGGVV C-terminal sequence
in beta-amyloid that is immunogenic. The epitope for
this sequence labels beta-amyloid in the Alzheimer’s brain
[28]. This pentapeptide is, per se, ﬁbrillogenic [49]. This
is a characteristic of both beta-amyloid and of HSV-1
glycoprotein B peptide fragments containing this sequence.
The viral glycoproteinBfragments formthioﬂavin T positive
ﬁbrils which accelerate beta-amyloid ﬁbril formation and
are neurotoxic in cell culture [50]. Other stretches of beta-
amyloid are homologous to a diverse set of viral, bacterial,
fungal, and allergenic proteins, likely providing the source of
the autoantibodies in the ageing population [32].
Antibodies to beta-amyloid have been suggested as a
therapeutic option in Alzheimer’s disease. The potential
use of beta-amyloid antibodies is based on their ability
to reduce plaque burden and neurite dystrophy in APP
transgenic mice [51]. Several studies have demonstrated
that beta-amyloid antibodies reduce plaque burden in APP
transgenic models and that they can also improve cognitiveInternational Journal of Alzheimer’s Disease 13
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VGGVV: Aeromonas phage, Allpahuayo virus, Clostridium phage, Dengue virus,
Ectromelia virus, Enterobacteria phage, Escherichia phage, Feline Calicivirus,
Haemophilusphage, Halomonas phage, Hepatitis C , Hepatitis delta, HHV-6, HHV-6B,
HSV-1, HSV-2, Human coronavirus, Human enterovirus, Human immunodeﬁciency virus 1,
Human adenovirus 8, Iguape virus, Infectious bronchitis virus, Lactate dehydrogenase-
elevatin g virus, Lactococcus phage, Microcystis phage, Mycobacterium phage,
Polyomavirus HPyV7, Prochlorococcus phage, Pseudomonas phage, Roseophage,
Salmonella phage, Shigella phage, Streptococcus,phage, Synechococcus phage, Variola
virus, Vibrio phage, Viral hemorrhagic septicemia virus, Yellow fever
(b)
Figure 2: The B cell and T cell immunogenicity proﬁle for the beta-amyloid peptide. According to the servers, antigenicity values of >0.35
(B cell) or 0.5 (T cell) are considered immunogenic. The sequences of herpes simplex viral proteins that align with beta-amyloid are shown.
Space: non-identical amino acid; +: conserved amino acid with similar physicochemical properties. Viruses and phages containing the
VGGVV sequence, which has been used as an epitope to label beta-amyloid in Alzheimer’s disease, are also shown.
performance [52]. However amyloid antibodies extracted
from the serum of old APP transgenic mice potentiate the
toxicity of beta-amyloid, and Alzheimer’s disease patients
display an enhanced immune response to the peptide [53].
Againintransgenic mice,diﬀerentimmunebackgroundscan
inﬂuence the type of immune responses elicited by beta-
amyloid.Forexample,BandTcellresponsestobeta-amyloid
can be modiﬁed in HLA-DR3, -DR4, -DQ6, or -DQ8
transgenic mice [54] .H L A - a n t i g e nd i v e r s i t yi nM a ni sa l s o
likely to determine the outcome of beta-amyloid/antibody
interactions. A large number of Alzheimer’s disease sus-
ceptibility gene candidates, including clusterin and com-
plement receptor 1, as well as diverse interleukins and
othercytokines,Creactive protein, HLA-antigens,Fcepsilon
and Toll receptors, and the viral-activated kinase PKR, are
intimately concerned with pathogen defence and or the
immune system, supporting a genetic contribution to the
immune pathogenesis of Alzheimer’s disease (see http://
www.polygenicpathways.co.uk/alzpolys.html.)
Beta-amyloid vaccination in Alzheimer’s disease (against
Abeta1−42) has so far not been successful and sadly resulted
in meningoencephalitis and the death of a patient [55].
While certain beta-amyloid antibodies may reduce plaque
burden, there is an evident risk that they may also trigger
an autoimmune response, potentially killing beta-amyloid
containing neurones. Catalytic autoantibodies are less able14 International Journal of Alzheimer’s Disease
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Figure 3: The B cell and T cell immunogenicity proﬁle for the tau protein. The sequences of herpes simplex viral proteins that align with
tau are shown.Space: non-identical amino acid; +: conserved amino acid with similar physicochemical properties.
to form stable immune complexes and likely represent the
safest way forward in this area [56, 57]. Given the homology
of beta-amyloid to so many viruses and the potential dangers
of autoimmunity, as well as the clearly toxic eﬀects of tau
immunisation,thepursuitofclinicaltrialswithbeta-amyloid
antibodies, with the exception of catalyticforms, must surely
be questioned.
8.Conclusions
Alzheimer’s disease proteins encoded by all of the major
genetic players in Alzheimer’s disease and many other
relevant proteins are homologous to proteins from the
herpes simplex virus, conﬁrming the implication of this
v i r u sa sac a u s a t i v ea g e n ti nt h i sd i s e a s e[ 48, 50, 58–
70]. Because of homology to other viruses and pathogens,
t h e s et o om a yb ei m p l i c a t e d .T h e s ei n c l u d eH H V - 6 ,t h e
cytomegalovirus, Borrelia, Burgdorferi, Chlamydia Pneu-
moniae, Helicobacter pylori, Cryptococcus neoformans and
bacteria promoting gum disease, such as P. Gingivalis, all
of which also express proteins homologous to the products
of numerous Alzheimer’s disease susceptibility genes (see
http://www.polygenicpathways.co.uk/Alzheimer.htm).
No vaccine against HSV-1 exists, but in the long term,
may perhaps beabletopreventAlzheimer’sdisease, although
the potential dangers of vaccine-related autoimmunity evi-
dently need to be addressed. Interestingly, cancer-causing
viruses including the Epstein-Barr-virus, hepatitis b, and
the papillomavirus align with the peptide stretch within
beta-amyloid [32] that is cleaved by the beneﬁcial catalytic
autoantibodies to beta-amyloid [56, 57]. Cancer is inversely
associated with the risk of developing Alzheimer’s disease
[71, 72]. As a vaccine to the human papillomavirus already
exists to prevent cervical cancer [73], it may well have a
role to play in the prevention or therapy of Alzheimer’s
disease, again with due regard to the problem of vaccine-
related autoimmunity. Alternatively, immunisation with this
beneﬁcial region of the beta-amyloid peptide might be
considered as a viable therapeutic option.
Many of the toxic eﬀects of HSV-1 infection are likely
to be related to autoimmunity, caused by antibodies to the
viral proteins that also target their human counterparts.
In this case, it is possible that immunosuppressant therapyInternational Journal of Alzheimer’s Disease 15
may be of beneﬁt in Alzheimer’s disease patients and
also that aggressive antiviral therapy should be pursued.
Immunoadsorption of tau and beta-amyloid antibodies, a
technique used to good eﬀect in certain patients with myas-
thenia gravis (characterised by autoantibodies to nicotinic
receptors) [74] may also be of beneﬁt. As other pathogens
may also demonstrate this type of mimicry, detailed and
regular pathogen screens in the ageing population and in the
early stages of Alzheimer’s patients may also be of use.
Alzheimer’s disease thus appears to be one, probably of
many, “pathogenetic” diseases, caused by viruses and other
pathogens, but dependent on our genes, which dictate the
protein sequences that match those in particular subsets of
pathogen proteins. There are almost 3,000 viral genomes
in the NCBI database, probably reﬂecting but a small
proportion of those existing on the planet. In addition, as
viruses regularly mutate with replication there are likely to
be multiple strains of HSV-1 (and other viruses), only one
of which is recorded in the NCBI database. Nevertheless,
with current bioinformatics techniques, it should be possible
to rapidly identify all vatches in the human proteome, to
match them to particular viruses (and other pathogens,
Bacteria, fungi, yeast, parasites, etc.), and to pair these with
diverse human diseases. Our understanding of this universal
phenomenon could radically change the face of therapy in a
variety of human conditions.
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